Centiva Capital LP Reduces Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Centiva Capital LP reduced its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 89.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 663 shares of the biotechnology company's stock after selling 5,648 shares during the quarter. Centiva Capital LP's holdings in Axon Enterprise were worth $394,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Cetera Investment Advisers increased its position in shares of Axon Enterprise by 1.0% during the fourth quarter. Cetera Investment Advisers now owns 23,009 shares of the biotechnology company's stock worth $13,675,000 after acquiring an additional 236 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Axon Enterprise during the 4th quarter valued at about $3,506,000. Capstone Investment Advisors LLC raised its position in Axon Enterprise by 4.7% in the 4th quarter. Capstone Investment Advisors LLC now owns 1,505 shares of the biotechnology company's stock worth $894,000 after purchasing an additional 67 shares during the period. Captrust Financial Advisors raised its holdings in shares of Axon Enterprise by 19.5% during the fourth quarter. Captrust Financial Advisors now owns 14,821 shares of the biotechnology company's stock valued at $8,809,000 after acquiring an additional 2,415 shares in the last quarter. Finally, Baker Avenue Asset Management LP purchased a new stake in Axon Enterprise in the fourth quarter worth $255,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on AXON. Barclays upped their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. The Goldman Sachs Group lifted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Needham & Company LLC raised their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Stock Down 0.0%

Shares of NASDAQ:AXON traded down $0.14 on Thursday, reaching $728.39. The company had a trading volume of 567,282 shares, compared to its average volume of 762,145. The firm's 50 day simple moving average is $576.22 and its 200-day simple moving average is $589.48. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $732.22. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $56.71 billion, a PE ratio of 188.21, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.15 earnings per share. As a group, analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, Director Matthew R. Mcbrady sold 400 shares of the business's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total transaction of $287,360.00. Following the transaction, the director now directly owns 3,492 shares in the company, valued at approximately $2,508,652.80. The trade was a 10.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the transaction, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,764 shares of company stock worth $14,856,635 in the last 90 days. Corporate insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.